New resource available  view now

Decoding Tau Heterogeneity: IGC Pharma Presents Novel Biomarker Research at the 2026 Global Tau Conference

Understanding why some Alzheimer's patients decline faster than others, even with similar levels of tau pathology  remains one of the field's most pressing questions.

At the 2026 Global Tau Conference in Washington, D.C., our research team presented a novel approach using Shannon entropy, a metric from information theory, to quantify how tau distributes across brain regions. Analyzing over 1,570 tau-PET scans from 931 ADNI participants, we found that patients with more concentrated (focal) tau patterns showed worse cognitive outcomes and faster future tau accumulation, particularly among amyloid-positive APOE4 carriers. These findings suggest that measuring not just how much tau is present, but how it is spatially organized, could open new avenues for patient stratification and clinical trial design in Alzheimer’s disease.

Decoding Tau Heterogeneity: IGC Pharma Presents Novel Biomarker Research at the 2026 Global Tau Conference

Related Posts